EMHA’s 2019 Activities report and agenda of 2019 was fulfilled with activities, meetings and actions under the campaign name of #LightToMigraine. Read the full activities report. Click here to read the complete report.
EMHA’s 2019 Activities report Read More »
European survey on migraine in the workplace. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. Read de complete document in our Study section About the study of Migraine in the workplace The objective
Migraine in the workplace Read More »
EMHA and Allergan. Elena Ruiz de la Torre, Executive Director of EMHA attended a business meeting on 23 January with the Allergan Company. The purpose of the meeting was to share ideas and priorities to explore areas of collaboration and identify opportunities between EMHA and Allergan. We also took the opportunity to share the
European survey on migraine at work. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. The objective of this study is to know the situation of migraine workers within the workplace and compare the
Each year, September 12th is the European Migraine Day of Action. Today, EMHA’s President and Executive Director have been invited by MEP Esteban Gonzalez Pons and MEP Dolors Montserrat to the European Parliament to discuss about how to better help the affected ones to give light to the disease and how to improve the life
European Migraine Day of Action with MEPS in the European Parliament Read More »
Elena Ruiz de la Torre, presented at the IHC the movement #LightToMigraine, an initiative to
mobilize and activate the Affected Migraine community and show how extraordinary they are.
The Dawn of a New Era in Migraine Awareness Read More »
Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she
New drugs, decades in the making, are providing relief for migraines. Read More »
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes
“Green light” to Lilly’s monoclonal antibody to migraine Read More »
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least
Lilly Receives Positive CHMP Opinion for Emgality Read More »
INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available
Lilly’s Emgality Approved Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
